Business Information
The group's principal activities are the discovery and development of medicines that treat cancer by regulating cell signaling with small molecules. The group's lead product candidate, ap23573, is in phase 1 clinical trials and is used for the treatment of solid tumors and other malignancies. Other product candidates include ap23464, to block the spread of cancer and treat certain forms of leukemia and ap23841, to treat primary bone cancers, such as osteogenic sarcomas and cancer that has spread to bone. In addition, the group has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs to regulate nf-kb cell-signaling activity, which can be used to treat disorders such as inflammation, cancer and osteoporosis.
|
|
Name |
Title
|
Email
|
| Harvey Berger | Chmn., CEO | N/A | | Sandford Smith | Vice Chmn. | N/A | | Camille Bedrosian | Chief Medical Officer, VP | Available | | Edward Fitzgerald | Sr. VP - Finance, Corporate Operations, CFO, Treasurer | N/A | | John Iuliucci | Chief Development Officer, Sr. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 896 | (61,928) | | 2005 | 1,217 | (55,482) | | 2004 | 742 | (35,573)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
